Skip to main content
Grafa
Health

Neuren declares interim dividend following royalty growth

Share
  • Neuren Pharmaceuticals declared its first-ever dividend programme alongside its H1 2026 financial results.
  • The company announced a fully franked interim dividend of 15 cents per share despite net profit dropping 68% to $4.9 million.
  • Growth in DAYBUE royalty revenue, which rose 29% to US$23 million, is anchoring the new ongoing dividend policy.

Neuren Pharmaceuticals (ASX:NEU) declared a fully franked interim dividend of 15 cents per share for H1 2026 as part of its first-ever dividend policy to return capital to shareholders.

The new payout comes as revenue increased 8% to $42.7 million, while net profit after tax fell to $84.9 million compared to $15 million in H1 2025.

"Neuren’s substantial income from trofinetide means that we are in the enviable position of being able to fund all development programmes for NNZ-2591 aiming for significant capital appreciation," said Neuren Pharmaceuticals CEO Jon Pilcher.

Under the policy, the company targets a payout ratio between 70% and 100% of available after-tax royalty income after subtracting administrative costs.

Following the announcement, the Neuren Pharmaceuticals share price was down at $20.52.

Partner Acadia Pharmaceuticals reported DAYBUE net sales of US$226 million for H1 2026, marking a 25% increase driven by adoption of its powder formulation.

Acadia updated its full-year 2026 global net sales guidance for DAYBUE to between US$480 million and US$510 million.

Frequently asked questions